Valuation: Alzinova AB

Market Cap 19Cr 2.02Cr 1.75Cr 1.64Cr 1.49Cr 2.81Cr 193.46Cr 2.85Cr 7.53Cr 97Cr 7.6Cr 7.43Cr 322.41Cr P/E 2026 *
-3.61x
P/E 2027 * -2.57x
Enterprise Value 18Cr 1.85Cr 1.6Cr 1.5Cr 1.37Cr 2.57Cr 177.35Cr 2.61Cr 6.9Cr 89Cr 6.96Cr 6.81Cr 295.56Cr EV / Sales 2026 *
5.62x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day-2.77%
1 week-10.90%
Current month-18.28%
1 month+35.82%
3 months+108.12%
6 months+31.67%
Current year+14.35%
1 week 0.91
Extreme 0.911
1.06
1 month 0.61
Extreme 0.61
1.23
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.77%-10.90%-17.71%-72.32% 2.08Cr
+0.68%-1.01%+2.16%+18.05% 4.84TCr
+4.07%+2.43%+481.62%+623.80% 4.37TCr
+4.33%+0.98%+13.53%+88.53% 3.95TCr
+1.94%-0.31%+25.29%+12.62% 3.9TCr
-0.50%+0.85%+20.60%+58.18% 3.26TCr
-0.44%-3.22% - - 1.63TCr
+3.22%-0.88%+28.99%+135.47% 1.61TCr
-0.62%+0.29%+3.46%+25.58% 1.42TCr
+2.35%+3.48%+82.60%+43.41% 1.34TCr
Average +1.23%-1.15%+71.17%+103.70% 2.63TCr
Weighted average by Cap. +1.94%-0.62%+101.06%+150.40%

Financials

2026 *2027 *
Net sales 3.14Cr 33.02L 28.51L 26.74L 24.36L 45.8L 32Cr 46.44L 1.23Cr 16Cr 1.24Cr 1.21Cr 53Cr -
Net income -32L -3L -3L -3L -2L -5L -3.22Cr -5L -12.54L -1.61Cr -12.65L -12.38L -5.37Cr -5.04Cr -53.03L -45.78L -42.95L -39.12L -73.56L -51Cr -74.58L -1.97Cr -25Cr -1.99Cr -1.95Cr -85Cr
Net Debt -1.6Cr -16.85L -14.55L -13.65L -12.43L -23.38L -16Cr -23.7L -62.7L -8.07Cr -63.27L -61.9L -27Cr -1.9Cr -20.01L -17.28L -16.21L -14.76L -27.76L -19Cr -28.14L -74.45L -9.59Cr -75.13L -73.51L -32Cr
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
17/26/17 SEK 0.9480 -2.77% 8,00,829
14/26/14 SEK 0.9750 -2.69% 13,35,012
13/26/13 SEK 1.002 +8.68% 13,90,873
12/26/12 SEK 0.9220 -8.53% 23,39,356
11/26/11 SEK 1.008 -1.18% 12,41,433

Annual profits - Rate of surprise